Table 1.
Patient characteristics stratified by the MRI radiomics signature in patients with all-stages and early-stage ENKTCL.
| MRI radiomics signature | ||||||
|---|---|---|---|---|---|---|
| Total | Type I | Type II | ||||
| Characteristic | No. (%) | No. (%) | No. (%) | P | ||
| All Stages (n = 176) | 176 | 65 | 111 | |||
| Gender, male | 128 (72.7) | 46 (70.8) | 82 (73.9) | 0.655 | ||
| Age, > 60 years | 26 (14.8) | 10 (15.4) | 16 (14.4) | 0.861 | ||
| B symptoms | 82 (46.6) | 22 (33.8) | 60 (54.1) | 0.009 | ||
| ECOG score ≥ 2 | 10 (5.7) | 1 (1.5) | 9 (8.1) | 0.094 | ||
| Stage I–II | 166 (94.3) | 63 (96.9) | 103 (92.8) | < 0.001 | ||
| PTI | 126 (71.6) | 23 (35.4) | 103 (92.8) | < 0.001 | ||
| Elevated LDH | 46 (26.1) | 9 (13.8) | 37 (33.3) | 0.005 | ||
| Primary site, nasal cavity | 141 (80.1) | 58 (89.2) | 83 (74.8) | 0.020 | ||
| Stage I–II (n = 166) | 166 | 63 | 103 | |||
| Gender, male | 121 (72.9) | 45 (71.4) | 76 (73.8) | 0.740 | ||
| Age, > 60 years | 25 (15.1) | 10 (15.9) | 15 (14.6) | 0.819 | ||
| B symptoms | 77 (46.4) | 21 (33.3) | 56 (54.4) | 0.008 | ||
| ECOG score ≥ 2 | 10 (6.0) | 1 (1.6) | 9 (8.7) | 0.091 | ||
| Stage II | 65 (39.2) | 3 (4.8) | 62 (60.2) | < 0.001 | ||
| Elevated LDH | 43 (25.9) | 9 (14.3) | 34 (33.0) | 0.008 | ||
| PTI | 116 (69.9) | 21 (33.3) | 95 (92.2) | < 0.001 | ||
| Primary site, nasal cavity | 134 (80.7) | 56 (88.9) | 78 (75.7) | 0.037 | ||
Abbreviations: ENKTCL extranodal nasal-type NK/T-cell lymphoma, MRI magnetic resonance imaging, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PTI primary tumor invasion.